Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3689L |
Ruboxistaurin mesylate
LY-333531,LY333531,LY 333531,LY-333531 Mesylate |
||
Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/ | |||
T69990 |
Ruboxistaurin mesylate monohydrate
|
||
Ruboxistaurin mesylate monohydrate is a PKC beta inhibitor potentially for the treatment of diabetic nephropathy and diabetic macular edema. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. | |||
T69989 | (S)-Pomalidomide | ||
(S)-Pomalidomide is an inhibitor of angiogenesis and growth of B-cell neoplasias, which induces complete regressions of Burkitt's lymphoma cell tumors. |